We thank the authors for their interest in our meta-analysis; indeed, their concerns reflect many we articulated [1, 2]. We used the published literature to conclude ‘there is some evidence that tocilizumab use may be associated with a short-term mortality benefit in patients with COVID-19’. This uncertainty has been extended by the recent WHO meta-analysis [3] which incorporated as yet unpublished trials as well as longer-term outcomes provided by some of the trialists to include nearly 11,000 patients. The overall conclusion of this meta-analysis was stronger as the odds ratio for 28-day mortality did not cross the line of identity. However, the subgroup analyses presented within this paper further reinforce our concerns. Outcome benefit is restricted only to males and, at randomisation, only to subgroups receiving corticosteroids, oxygen or non-invasive ventilation, or with mid-range CRP values (75–149 mcg/ml). Of note, 28-day mortality benefit was only seen in open-label studies and not in placebo-controlled studies, and no survival benefit was seen in either of these subgroups at 90 days. Our meta-analysis demonstrates lack of benefit seen with trials with low risk of bias. With a number of trials being open labelled, and crossover of patients between treatment and control groups, the overall quality of evidence was low.

To challenge the argument made by Dr Kuindersma and Dr Spronk [4], do we simply ignore these sizeable subgroups or use them to generate hypotheses and conduct prospective studies to better understand the science underlying both COVID-19 pathophysiology and individual responses to any intervention? We would disagree with them on the prognostic utility of the baseline CRP value. Indeed, we [5, 6] and many others have reported that CRP is a good prognosticator of both the need for invasive ventilation and mortality in COVID-19 disease. With respect to IL-6 blockade, the WHO meta-analysis reflects no benefit both in those on invasive ventilation [OR 0.95; 95% CI (0.78–1.16)] and with CRP values ≥ 150 mcg/l [OR 0.96; 95% CI (0.83–1.11)]; these findings are internally consistent and suggest less/no benefit in the sickest cohort of patients.

We are very sympathetic to the notion that ferritin, IL-6 or other biomarkers, or combinations thereof, may be superior tools to identify which patients are likely to benefit from IL-6 blockade. Unfortunately, this too remains hypothetical. The randomised studies performed to date have not provided any data to offer a clear steer in this regard. Obviously, any putative theranostic would need to be prospectively validated. As the editorial accompanying our article notes [7], whether this will happen is doubtful. The possibility of harm associated with tocilizumab use in a subset of patients with COVID-19 is of concern, with some trials showing no overall benefit and others being terminated early due to harm [8]. We are therefore completely in agreement that the ultimate goal should be an individualised treatment approach underpinned by sound scientific understanding.

Funding
None.

Declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 25 July 2021 Accepted: 26 July 2021
Published online: 6 August 2021
References

1. Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N (2021) Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med 47(6):641–652. doi.org/10.1007/s00134-021-06416-z

2. Singer M, Kalil A (2021) Do not just sit there, do something … but do no harm: the worrying aspects of COVID-19 experimental interventions. Intensive Care Med. doi.org/10.1007/s00134-021-06460-9

3. Group WHOREAfC-TW, Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyer SL, Derde LPC, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kamb K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchant N, Misran NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Siwaplasingam S, Soin AS, Staplin N, Stone JH, Strobl-C更深van Cullberg J, Torre-Cineros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westernwell PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC (2021) Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. doi.org/10.1016/S2665-9913(20)30275-7

4. Kuindersma M, Spronk PE (2021) “L’histoire se repete”, one size does not fit all. Intensive Care Med. doi.org/10.1007/s00134-021-06433-2

5. Arina P, Bax B, Moro V, Patel H, Ambler G, Group UCLCCC-R (2021) Discriminating between CPAP success and failure in COVID-19 patients with severe respiratory failure. Intensive Care Med 47(2):237–239. doi.org/10.1007/s00134-020-06304-y

6. Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddie T, Khan E, Mehta P, Martin-Gutierrez L, Waddington KE, Robinson GA, Ribeiro Santos L, McLoughlin E, Snell A, Adelney C, Schim van der Loeff I, Baker KF, Duncan CIA, Hannah AT, Lendrem BC, De Soysa A, Peng J, JBari H, Greenwood M, Hawkins E, Peckham H, Marks M, Randles T, Lintel A, Williams B, Brown M, Singer M, West J, Jury EC, Collin M, Tattersall RS (2020) COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Respir Med 2(10):e594–e602. doi.org/10.1016/S2213-2600(20)30275-7

7. Butler E, Munch MW, Venkatesh B (2021) Time for tocilizumab in COVID-19. Intensive Care Med 47(6):692–694. doi.org/10.1007/s00134-021-06441-y

8. Veiga VC, Prats J, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, Machado FR, Lopes RD, Berwanger O, Azevedo LCP, Avezum A, Lisboa TC, Rojas SSO, Coelho JC, Leite RT, Carvalho JC, Andrade LEC, Sanders AF, Pintao MCT, Castro CG Jr, Santos SV, de Almeida TML, Costa AN, Gebara OCE, de Freitas FGR, Pacheco ES, Machado DJB, Martin J, Concejiao FG, Siqueira SRR, Damiani LP, Ishihara LM, Schneider D, de Souza D, Cavalcanti AB, Scheinberg P, Coalition covid-19 Brazil VII (2021) Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ 372:n84. doi.org/10.1136/bmj.n84